
BofA Securities upgrades Bayer to “buy” on drug outlook and legal upside
Investing.com -- BofA Securities has raised its rating on Bayer (ETR:BAYGN) to “buy” from “neutral,” increasing its price objective to €30 from €27, citing improved expectations for the experimental stroke drug asundexian and the potential resolution of …